GoldenGolden
Abingworth (company)

Abingworth (company)

Abingworth is a venture capital firm investing in seed-stage life sciences startups.

Abingworth is a venture capital firm founded in 1973. The firm's headquarters is located in London, United Kingdom, with additional offices in the United States at San Francisco and Boston. As of October 2019, Abingworth has sold off its ownership in 134 companies and is currently managing a portfolio of 25 companies.

Abingworth focuses on funding companies based in Europe and the United States. Sector-wise, Abingworth provides funding for companies in the life sciences industry, with a specific interest in fields such as biotherapeutics, small molecules, nucleic acid therapeutics, and vaccines. For each company, the firm allocates an investment total at a range of $15-$30 million.

Timeline

Funded Companies

Company
Description
Industry
Website
Location
Alnylam Pharmaceuticals

A biopharmaceutical company focusing on the discovery, development, and commercialization of RNAi therapeutics for treating rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS) diseases.

A biopharmaceutical and gene editing company founded in 2013. CRISPR Therapeutics AG is based in Zug, Switzerland and CRISPR Therapeutics, Inc. is the U.S. subsidiary with R&D operations in Cambridge, Massachusetts and business offices in London, U.K.

Labcyte is a global biotechnology tools company headquartered in San Jose, California, that develops tools for liquid handling.

A company focused on development of products to treat central nervous system disorders, pain and rare diseases

A company developing therapies for psychological and neurological illnesses

A technology company with a sensory interface platform which allows users to speak and hear clearly in extreme noise, wind, under mask and under water. It was founded in 2010 and is located in San Mateo, California.

Scorpion Therapeutics is a Boston-based company founded in 2020.

Chiasma Pharma is a Waltham, Massachusetts-based biopharmaceutical company developing oral drugs for the treatment of orphan diseases.

An independent vaccine platform in California that focuses on delivering best-in-class conjugate vaccines and complex antigen-based vaccines to prevent deadly infectious diseases.

Avedro is a company that is advancing the field of Corneal Remodeling.

Personalis is a Menlo Park, California-based biotechnology company working to commercialize cancer immunotherapies founded in 2011.

Dicerna Pharmaceuticals is a company that focuses on the discovery and development of treatments for inherited diseases.

Pathwork Diagnostics is a Redwood City, California-based molecular diagnostics for oncology company founded by Glenda G. Anderson.

GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.

PrimeraDx is a molecular diagnostics company that develops and commercializes a clinical platform

Clovis Oncology is a Boulder, Colorado-based biopharmaceutical company developing and commercializing cancer treatments.

TruCode Gene Repair is a South San Francisco, California-based company founded by Marshall Fordyce.

VenatorRx Pharmaceuticals is a Malvern, Pennsylvania-based biotechnology and pharmaceutical company working in the discovery and development of anti-infectives to treat multi-drug-resistant bacterial infections and viral infections.

A company developing RNA-based therapeutics for genetic disorders, infections and cancer

Epigenomics AG is a Berlin-based molecular diagnostics company focused on the development of diagnostic tests for cancer.

A company dedicated on the discovery and development of small molecule therapeutics to treat cancer

A biopharmaceutical company developing small molecule drugs for asthma, chronic allergy and inflammatory conditions

Reneo Pharma Ltd is a Sandwich, Kent-based company founded in 2018.

35 Results
Results per page:
Page 1 of 2

People

Name
Role
LinkedIn

Alex Asquith

Counsel

Andrew Sinclair

Partner, Portfolio Manager

Bali Muralidhar

Partner

Brian Gallagher

Partner

Genghis Lloyd-Harris

Managing Partner

Jackie Grant

Principal

James Abell

Partner and CFO

John Heard

Partner and General Counsel

Ken Haas

Partner

Kurt von Emster

Managing Partner

Sarah Shackelton

Partner, Marketing and Talent

Shelley Chu

Partner

Tim Haines

Chairman & Managing Partner

Vincent Miles

Partner

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Mark Terry
May 10, 2021
BioSpace
London-based venture capital fund Abingworth closed on a new Clinical Co-Development Fund now at $582 million. The fund's original target was just at $350 million.
Abingworth
May 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- Abingworth, a leading international life sciences investment group, today announced the final closing of its new Clinical Co-Development Fund...
Nick Paul
May 7, 2021
FierceBiotech
Abingworth has raised $582 million for its second clinical co-development fund. The fund, ACCD 2, equips Abingworth to make triple-digit million investments in late-stage clinical programs.
Abingworth
February 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- Abingworth, a leading international life sciences investment group, today announced the final closing of its latest transatlantic venture fund,...
Nick Paul
February 2, 2021
FierceBiotech
Abingworth has raised a $465 million life sciences fund, positioning it to build on earlier investments in biotechs including Alnylam and CRISPR Therapeutics. The transatlantic fund will follow a similar playbook to its seven predecessors, with slight tweaks such as a greater interest in vaccines and CNS diseases.
Abingworth
December 21, 2020
www.prnewswire.com:443
/PRNewswire/ -- Abingworth, the international investment group dedicated to life sciences, is pleased to announce the promotion of Bali Muralidhar MD PhD to...
Ben Adams
December 16, 2020
FierceBiotech
University of Florida spinout Atsena Therapeutics has closed a $55 million financing that will help take its gene therapy for a common cause of blindness in children into pivotal trials.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.